Recent advances in lean NAFLD - 31/08/22
, Yanqi Dang a, ⁎ Abstract |
As the predominant type of chronic liver disease, the growing prevalence of nonalcoholic fatty liver disease (NAFLD) has become a concern worldwide. Although obesity plays the most pivotal role in NAFLD, approximately 10–20% of individuals with NAFLD who are not overweight or obese (BMI < 25 kg/m2, or BMI < 23 kg/m2 in Asians) have “lean NAFLD.” Lean individuals with NAFLD have a lower prevalence of diabetes, hypertension, hypertriglyceridemia, central obesity, and metabolic syndrome than nonlean individuals with NAFLD, but higher fibrosis scores and rates of cardiovascular morbidity and all-cause mortality in advanced stages. The pathophysiological mechanisms of lean NAFLD remain poorly understood. Studies have shown that lean NAFLD is more correlated with factors such as environmental, genetic susceptibility, and epigenetic regulation. This review will examine the way in which the research progress and characteristic of lean NAFLD, and explore the function of epigenetic modification to provide the basis for the clinical treatment and diagnosis of lean NAFLD.
El texto completo de este artículo está disponible en PDF.Graphical Abstract |
Highlights |
• | Approximately 10–20% of individuals with NAFLD have “lean NAFLD.” |
• | Lean individuals with NAFLD have a lower prevalence of diabetes, hypertension, hypertriglyceridemia, obesity, and metabolic syndrome, but higher fibrosis scores and rates of cardiovascular morbidity and all-cause mortality in advanced stages. |
• | Lean NAFLD is categorized into two broad subtypes based on epidemiology, natural history, and prognosis. |
• | The progression of lean NAFLD is affected by multiple epigenetic mechanisms. |
• | The development of an improved non-invasive assessment and animal models of lean NAFLD are urgent. |
Keywords : Lean nonalcoholic fatty liver disease, Metabolic risk, Delineation, Animal models, Epigenetic
Esquema
Vol 153
Artículo 113331- septembre 2022 Regresar al número
Artículo precedente
- Emerging roles and potential clinical applications of long non-coding RNAs in hepatocellular carcinoma
- Jiaqi Sheng, Enjun Lv, Limin Xia, Wenjie Huang
- Gene therapy clinical trials, where do we go? An overview
- Fatemeh Arabi, Vahid Mansouri, Naser Ahmadbeigi
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?